SOAANZ® (torsemide) tablets
Edema associated with heart failure and renal disease
ApprovedActive
Key Facts
Indication
Edema associated with heart failure and renal disease
Phase
Approved
Status
Active
Company
About Sarfez Pharmaceuticals
Sarfez Pharmaceuticals is a private, commercial-stage biotech founded in 2018, headquartered in San Diego, California. The company has successfully brought its lead product, SOAANZ® (a novel slow-release formulation of torsemide), to market for edema in heart failure and kidney disease patients. Its business model is centered on therapeutics, and it is currently in the revenue-generating stage, leveraging digital discount platforms like GoodRx for patient access. The company faces regulatory scrutiny, as evidenced by a recent FDA corrective communication, and operates in a competitive generic drug landscape.
View full company profile